GEROPHARM

Executive Summary

GEROPHARM is a leading Russian biopharmaceutical company specializing in insulin and biosimilar products, with a dominant domestic market share. The company leverages integrated R&D and large-scale manufacturing to address socially important diseases like diabetes. Its pipeline includes several Phase 3 biosimilar candidates, notably GP40071 (insulin aspart biosimilar) and GP40081 (insulin aspart premix biosimilar), which have completed trials, and GP404141, a romiplostim biosimilar currently in an active Phase 3 study. Regulatory approvals in Russia and potential expansion into neighboring markets represent key value drivers. However, geopolitical risks and reliance on the Russian market temper near-term upside. Overall, GEROPHARM remains a dominant local player with a focused biosimilar pipeline, but limited international exposure.

Upcoming Catalysts (preview)

• Q3 2026GP40071 biosimilar insulin aspart regulatory submission in Russia80% success
• Q4 2026GP404141 romiplostim biosimilar Phase 3 data readout60% success
• TBDPotential partnership or licensing deal for insulin portfolio in CIS markets40% success